Role of the β 1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo

Anesthesiology

Volumn 105, Issue 3, 2006, Pages 503-510

  Lange, Markus ^a   Smul, Thorsten M ^a   Blomeyer, Christoph A ^a   Redel, Andreas ^a   Klotz, Karl Norbert ^a   Roewer, Norbert ^a   Kehl, Franz ^a,b  

^a Department of Pharmacology ^*  (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DESFLURANE; ESMOLOL; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PENTOBARBITAL; SEVOFLURANE; ANESTHETIC AGENT; BETA 1 ADRENERGIC RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; POTASSIUM CHANNEL; PROPANOLAMINE DERIVATIVE;

ANESTHESIA INDUCTION; ANESTHESIA MECHANISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOPULMONARY HEMODYNAMICS; CHO CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORONARY RISK; DRUG RECEPTOR BINDING; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MALE; MINIMUM LUNG ALVEOLUS CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; ANIMAL; BLOOD PRESSURE; HEART RATE; PHYSIOLOGY;

ANESTHETICS; ANIMALS; BLOOD PRESSURE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART RATE; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MYOCARDIAL INFARCTION; POTASSIUM CHANNELS; PROPANOLAMINES; RABBITS; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 33748133067     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200609000-00014     Document Type: Article

References (45)

1. Ludwig LM, Weihrauch D, Kersten JR, Pagel PS, Warltier DC: Protein kinase C translocation and Src protein tyrosine kinase activation mediate isoflurane-induced preconditioning in vivo: Potential downstream targets of mitochondrial adenosine triphosphate-sensitive potassium channels and reactive oxygen species. ANESTHESIOLOGY 2004; 100:532-9
2. Toller WG, Kersten JR, Gross ER, Pagel PS, Warltier DC: Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. ANESTHESIOLOGY 2000; 92:1400-7
3. Kohro S, Hogan QH, Nakae Y, Yamakage M, Bosnjak ZJ: Anesthetic effects on mitochondrial ATP-sensitive K channel. ANESTHESIOLOGY 2001; 95:1435-40
4. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC: Isoflurane mimics ischemic preconditioning via activation of KATP channels: Reduction of myocardial infarct size with an acute memory phase. ANESTHESIOLOGY 1997; 87:361-70
5. Toller WG, Gross ER, Kersten JR, Pagel PS, Gross GJ, Warltier DC: Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels: Mechanism of desflurane-induced cardioprotection. ANESTHESIOLOGY 2000; 92:1731-9
6. Kersten JR, Orth KG, Pagel PS, Mei DA, Gross GJ, Warltier DC: Role of adenosine in isoflurane-induced cardioprotection. ANESTHESIOLOGY 1997; 86:1128-39
7. Okubo S, Tanabe Y, Takeda K, Kitayama M, Kanemitsu S, Kukreja RC, Takekoshi N: Ischemic preconditioning and morphine attenuate myocardial apoptosis and infarction after ischemia-reperfusion in rabbits: role of δ-opioid receptor. Am J Physiol Heart Circ Physiol 2004; 287:H1786-91
8. Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, Perez DM: α1A- but not α1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism. Cardiovasc Res 2005; 65:436-45
9. Lohse MJ, Engelhardt S, Eschenhagen T: What is the role of β-adrenergic signaling in heart failure? Circ Res 2003; 93:896-906
10. Communal C, Singh K, Sawyer DB, Colucci WS: Opposing effects of β1-and β2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210-2
11. Frances C, Nazeyrollas P, Prevost A, Moreau F, Pisani J, Davani S, Kantelip JP, Millart H: Role of β1- and β2-adrenoceptor subtypes in preconditioning against myocardial dysfunction after ischemia and reperfusion. J Cardiovasc Pharmacol 2003; 41:396-405
12. Lochner A, Genade S, Tromp E, Podzuweit T, Moolman JA: Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation 1999; 100:958-66
13. Horimoto H, Saltman AE, Gaudette GR, Krukenkamp IB: Nitric oxide-generating beta-adrenergic blocker nipradilol preserves postischemic cardiac function. Ann Thorac Surg 1999; 68:844-9
14. Suematsu Y, Anttila V, Takamoto S, del Nido P: Cardioprotection afforded by ischemic preconditioning interferes with chronic beta-blocker treatment. Scand Cardiovasc J 2004; 38:293-9
15. Bayne K: Revised Guide for the Care and Use of Laboratory Animals available. American Physiological Society. Physiologist 1996; 39:199, 208-11
16. Doorley BM, Waters SJ, Terrell RC, Robinson JL: MAC of I-653 in beagle dogs and New Zealand white rabbits. ANESTHESIOLOGY 1988; 69:89-91
17. Scheller MS, Saidman LJ, Partridge BL: MAC of sevoflurane in humans and the New Zealand white rabbit. Can J Anaesth 1988; 35:153-6
18. Warltier DC, Zyvoloski MG, Gross GJ, Hardman HF, Brooks HL: Determination of experimental myocardial infarct size. J Pharmacol Methods 1981; 6:199-210
19. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes: Characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:151-9
20. De Lean A, Hancock AA, Lefkowitz RJ: Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol 1982; 21:5-16
21. Cope DK, Impastato WK, Cohen MV, Downey JM: Volatile anesthetics protect the ischemic rabbit myocardium from infarction. ANESTHESIOLOGY 1997; 86:699-709
22. Piriou V, Chiari P, Lhuillier F, Bastien O, Loufoua J, Raisky O, David JS, Ovize M, Lehot JJ: Pharmacological preconditioning: Comparison of desflurane, sevoflurane, isoflurane and halothane in rabbit myocardium. Br J Anaesth 2002; 89:486-91
23. Kehl F, Pagel PS, Krolikowski JG, Gu W, Toller W, Warltier DC, Kersten JR: Isoflurane does not produce a second window of preconditioning against myocardial infarction in vivo. Anesth Analg 2002; 95:1162-8
24. Kehl F, Krolikowski JG, Mraovic B, Pagel PS, Warltier DC, Kersten JR: Is isoflurane-induced preconditioning dose related? ANESTHESIOLOGY 2002; 96:675-80
25. Toller WG, Kersten JR, Pagel PS, Hettrick DA, Warltier DC: Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs. ANESTHESIOLOGY 1999; 91:1437-46
26. Haessler R, Kuzume K, Chien GL, Wolff RA, Davis RF, Van Winkle DM: Anaesthetics alter the magnitude of infarct limitation by ischaemic preconditioning. Cardiovasc Res 1994; 28:1574-80
27. Han J, Kim N, Joo H, Kim E: Ketamine abolishes ischemic preconditioning through inhibition of K(ATP) channels in rabbit hearts. Am J Physiol Heart Circ Physiol 2002; 283:H13-21
28. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tanaka K, Tomiyama Y, Kitahata H, Nakaya Y: Molecular mechanisms underlying ketamine-mediated inhibition of sarcolemmal adenosine triphosphate-sensitive potassium channels. ANESTHESIOLOGY 2005; 102:93-101
29. ATP channel activity and cardiomyocyte protection. ANESTHESIOLOGY 2002; 97:15-23
30. Cason BA, Gamperl AK, Slocum RE, Hickey RF: Anesthetic-induced preconditioning: Previous administration of isoflurane decreases myocardial infarct size in rabbits. ANESTHESIOLOGY 1997; 87:1182-90
31. Nasa Y, Yabe K, Takeo S: Beta-adrenoceptor stimulation-mediated preconditioning-like cardioprotection in perfused rat hearts. J Cardiovasc Pharmacol 1997; 29:436-43
32. Robinet A, Hoizey G, Millart H: PI 3-kinase, protein kinase C, and protein kinase A are involved in the trigger phase of β1-adrenergic preconditioning. Cardiovasc Res 2005; 66:530-42
33. Hanouz JL, Yvon A, Massetti M, Lepage O, Babatasi G, Khayat A, Bricard H, Gerard JL: Mechanisms of desflurane-induced preconditioning in isolated human right atria in vitro. ANESTHESIOLOGY 2002; 97:33-41
34. ATP channels via multiple signaling pathways. ANESTHESIOLOGY 2002; 97:4-14
35. Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen Y, Lakatta EG, Xiao RP: Gi protein-mediated functional compartmentalization of cardiac beta 2-adrenergic signaling. J Biol Chem 1999; 274:22048-52
36. Xiao RP, Ji X, Lakatta EG: Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol 1995; 47:322-9
37. Belevych AE, Juranek I, Harvey RD: Protein kinase C regulates functional coupling of β1-adrenergic receptors to Gi/o-mediated responses in cardiac myocytes. FASEB J 2004; 18:367-9
38. Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390:88-91
39. Sato T, O'Rourke B, Marban E: Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C. Circ Res 1998; 83:110-4
40. Maxwell MP, Hearse DJ, Yellon DM: Species variation in the coronary collateral circulation during regional myocardial ischaemia: A critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987; 21:737-46
41. Volz-Zang C, Eckrich B, Jahn P, Schneidrowski B, Schulte B, Palm D: Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: Pharmacodynamic and pharmacokinetic properties. Eur J Clin Pharmacol 1994; 46:399-404
42. Arlock P, Wohlfart B, Sjoberg T, Steen S: The negative inotropic effect of esmolol on isolated cardiac muscle. Scand Cardiovasc J 2005; 39:250-4
43. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351:95-105
44. Chijiwa T, Mishima A, Hagiwara M, Sano M, Hayashi K, Inoue T, Naito K, Toshioka T, Hidaka H: Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5- isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990; 265:5267-72
45. Sun PW, Kyoung SY, Kim N, Boum YJ, Joo H, Warda M, Ko JH, Earm YE, Han J: The protein kinase A inhibitor, H-89, directly inhibits KATP and Kir channels in rabbit coronary arterial smooth muscle cells. Biochem Biophys Res Commun 2006; 340:1104-10